Overview: A gap in access to diabetes technology
New analysis shows that people from ethnic minority backgrounds in England are less likely to have access to the latest diabetes technology, even though they are more likely to live with diabetes. Devices such as continuous glucose monitors (CGMs) can improve blood sugar control, reduce complications, and increase patient autonomy. The discrepancy between disease burden and technology uptake raises important questions about equity in the NHS and the pathways that connect patients with innovative care tools.
Why technology matters for diabetes management
Advanced diabetes technology, including CGMs and automated insulin delivery systems, can transform everyday management. CGMs provide real‑time glucose data, alerts for highs and lows, and trends that help people adjust diet, activity, and medication. For those at higher risk of complications—which disproportionately includes people from some ethnic minority groups—access to precise, timely data can be life‑changing. Beyond clinical benefits, technology can ease the psychosocial burden of constant monitoring and empower patients to participate more actively in decision making with clinicians.
The study findings and what they mean
The analysis highlights a striking paradox: higher prevalence of diabetes among ethnic minority communities paired with lower uptake of diabetes tech. Several factors may contribute, including:
– Financial barriers: Out-of-pocket costs, even in systems with universal health care, can deter patients from adopting new devices when not fully funded by the NHS.
– Awareness and referral gaps: Primary care teams may be less likely to refer eligible patients to technology programs, possibly due to implicit bias or time constraints in busy practices.
– Digital literacy and support: Successful use of CGMs and related tools often requires training and ongoing support, which may be less accessible in some communities.
– Cultural and language barriers: Information about benefits, risks, and usage can be less accessible when language barriers exist or culturally tailored education is lacking.
– Trust and perceived relevance: Past experiences with healthcare systems can influence willingness to adopt new technologies.
Impact on health outcomes
Reduced access to diabetes technology among ethnic minority groups can contribute to widening health disparities. When patients miss out on CGMs or automated insulin delivery, they may experience more hyper- or hypoglycemic episodes, slower HbA1c improvement, and higher risk of long‑term complications. In turn, this can translate into greater use of emergency services and hospitalizations, reinforcing cycles of inequity.
What can be done to improve equity
Addressing these disparities requires coordinated efforts across policy, clinical practice, and community engagement:
– Policy reforms: Clear funding pathways for diabetes technology and transparent criteria for NHS provision can reduce financial barriers and simplify access.
– Education and outreach: Culturally competent education campaigns, translated materials, and community health workers can raise awareness and assist patients through the uptake process.
– Clinician training: Training for primary care teams on referral practices and the benefits of CGMs can close gaps in access.
– Support networks: Peer support groups and digital coaching can help patients learn to use devices confidently and sustain usage.
– Data-driven monitoring: Regular audits by ethnicity, geography, and socioeconomic status can identify gaps and target interventions where they are most needed.
Conclusion: A call for equitable innovation
As diabetes technology becomes more capable, ensuring equitable access is essential. The observed disparity is not only a statistic but a reflection of who benefits from medical innovation. By aligning funding, education, and practical support with the needs of ethnic minority communities, the healthcare system can ensure that technology boosts outcomes for everyone living with diabetes in England.
